• Shuang Li, Yong-Li Pan, Wenqiang Xin, and Chunhua Yan.
• Department of Respiratory Medicine, The Third People's Hospital of Longgang District, Shenzhen, P.R. China.
• Medicine (Baltimore). 2022 Oct 7; 101 (40): e29981e29981.

BackgroundFibrotic diseases take a very heavy toll in terms of morbidity and mortality equal to or even greater than that caused by metastatic cancer. This meta-analysis aimed to evaluate the effect of endothelin receptor antagonists on idiopathic pulmonary fibrosis.MethodA systematic search of the clinical trials from the Medline, Google Scholar, Cochrane Library, and PubMed electronic databases was performed. Stata version 12.0 statistical software (Stata Crop LP, College Station, TX) was adopted as statistical software.ResultA total of 5 studies, which included 1500 participants. Our analysis found there is no significant difference between using the endothelin receptor antagonists' group and placebo groups regarding the lung function via estimating both the change of forced vital capacity from baseline and DLco index. Exercise capacity and serious adverse effects are taken into consideration as well; however, there is still no significant change between the 2 groups.ConclusionThis meta-analysis provides insufficient evidence to support that endothelin receptor antagonists' administration provides a benefit among included participants who encounter idiopathic pulmonary fibrosis.Copyright © 2022 the Author(s). Published by Wolters Kluwer Health, Inc.

8 keywords...

hide…